Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective vigilantly but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my last several shares. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set out what follows prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire job interview that I came away with a bad impression of the company.

Irony of irony, the poor impression of mine of the business enterprise has grown steadily, yet the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein lies the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the expertise and also linked intellectual property coming from Progenics to CytoDyn, and approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) along with the first new drug program approval ($5 million), and even royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to buy a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and many therapies, it’s this single remedy and a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially beneficial therapy in dozens of indications.

The opening banner of its on its site (below) shows an active company with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple presentations in addition to multiple publications.

Could all of it be smoke and mirrors? That is a question I’ve been asking myself from the very beginning of the interest of mine in this business. Judging by way of the multiples of a huge number of several commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a classic battleground, or maybe some could say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *